Kiora Pharmaceuticals (KPRX) FDA Approvals $2.66 +0.01 (+0.19%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings Kiora Pharmaceuticals' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Kiora Pharmaceuticals (KPRX). Over the past two years, Kiora Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as KIO-300. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. KIO-300 FDA Regulatory Events KIO-300 is a drug developed by Kiora Pharmaceuticals for the following indication: in Preclinical Epilepsy Model. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Preclinical Data - June 18,2026Preclinical Data Drug: KIO-300Announced Date: June 18, 2026Indication: in Preclinical Epilepsy ModelAnnouncementKiora Pharmaceuticals announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.AI SummaryKiora Pharmaceuticals shared preclinical data showing that KIO-300 strongly reduced seizure-related electrical activity in an ex vivo temporal lobe epilepsy model. The results were presented in a poster at the Epilepsy Foundation Pipeline Conference in Leesburg, Virginia, on June 18-19, 2026. Researchers reported that the effect lasted during both treatment and washout, suggesting the compound stayed active in neural tissue for some time. They also found that KIO-300 did not reduce normal brain signaling, which points to a selective effect on abnormal activity rather than broad nervous system suppression. The company said the work builds on earlier retinal studies in which KIO-300 lowered harmful retinal hyperactivity by about 50%. Based on that science, Kiora is exploring whether its membrane-calming approach may also help in epilepsy. The poster was titled “KIO-300/BENAQ Modulates Epileptiform Activity in an Ex Vivo Hippocampal TLE Model.”Read Announcement Kiora Pharmaceuticals FDA Events - Frequently Asked Questions Has Kiora Pharmaceuticals received FDA approval? As of now, Kiora Pharmaceuticals (KPRX) has not received any FDA approvals for its therapy in the last two years. What drugs has Kiora Pharmaceuticals submitted to the FDA? In the past two years, Kiora Pharmaceuticals (KPRX) has reported FDA regulatory activity for KIO-300. What is the most recent FDA event for Kiora Pharmaceuticals? The most recent FDA-related event for Kiora Pharmaceuticals occurred on June 18, 2026, involving KIO-300. The update was categorized as "Preclinical Data," with the company reporting: "Kiora Pharmaceuticals announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA." What conditions do Kiora Pharmaceuticals' current drugs treat? Currently, Kiora Pharmaceuticals has one therapy (KIO-300) targeting the following condition: in Preclinical Epilepsy Model. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Akebia Therapeutics FDA EventsBioNTech FDA EventsCullinan Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsDare Bioscience FDA EventsDefinium Therapeutics FDA EventsDogwood Therapeutics FDA EventsImmunocore FDA EventsJanux Therapeutics FDA EventsLipocine FDA EventsMediWound FDA EventsPhio Pharmaceuticals FDA EventsRadiopharm Theranostics FDA EventsTenaya Therapeutics FDA EventsJohnson & Johnson FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Veru FDA Events Incannex Healthcare FDA Events Karyopharm Therapeutics FDA Events Cassava Sciences FDA Events Actuate Therapeutics FDA Events MIRA Pharmaceuticals FDA Events Optimi Health FDA Events Tvardi Therapeutics FDA Events Polyrizon FDA Events Cellectar Biosciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:KPRX last updated on 6/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredEvery Major Market Reset Had These 3 Warning Signs First. All 3 Are Flashing Right Now.U.S. debt is closing in on 38 trillion as foreign buyers pull back, tightening liquidity across markets. Th...Golden Crest Metals | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe Flaw Your Financial Advisor Will Not NameThe U.S. government values its gold at $42 an ounce, a price set by Congress in 1973 and never updated. Gold t...Monetary Gold | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Preclinical Data - June 18,2026Preclinical Data Drug: KIO-300Announced Date: June 18, 2026Indication: in Preclinical Epilepsy ModelAnnouncementKiora Pharmaceuticals announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.AI SummaryKiora Pharmaceuticals shared preclinical data showing that KIO-300 strongly reduced seizure-related electrical activity in an ex vivo temporal lobe epilepsy model. The results were presented in a poster at the Epilepsy Foundation Pipeline Conference in Leesburg, Virginia, on June 18-19, 2026. Researchers reported that the effect lasted during both treatment and washout, suggesting the compound stayed active in neural tissue for some time. They also found that KIO-300 did not reduce normal brain signaling, which points to a selective effect on abnormal activity rather than broad nervous system suppression. The company said the work builds on earlier retinal studies in which KIO-300 lowered harmful retinal hyperactivity by about 50%. Based on that science, Kiora is exploring whether its membrane-calming approach may also help in epilepsy. The poster was titled “KIO-300/BENAQ Modulates Epileptiform Activity in an Ex Vivo Hippocampal TLE Model.”Read Announcement
